180 related articles for article (PubMed ID: 19632582)
1. Prior human leukocyte antigen-allosensitization and left ventricular assist device type affect degree of post-implantation human leukocyte antigen-allosensitization.
Drakos SG; Kfoury AG; Kotter JR; Reid BB; Clayson SE; Selzman CH; Stehlik J; Fisher PW; Merida M; Eckels DD; Brunisholz K; Horne BD; Stoker S; Li DY; Renlund DG
J Heart Lung Transplant; 2009 Aug; 28(8):838-42. PubMed ID: 19632582
[TBL] [Abstract][Full Text] [Related]
2. Low-dose prophylactic intravenous immunoglobulin does not prevent HLA sensitization in left ventricular assist device recipients.
Drakos SG; Kfoury AG; Long JW; Stringham JC; Fuller TC; Nelson KE; Campbell BK; Gilbert EM; Renlund DG
Ann Thorac Surg; 2006 Sep; 82(3):889-93. PubMed ID: 16928502
[TBL] [Abstract][Full Text] [Related]
3. HLA and MICA allosensitization patterns among patients supported by ventricular assist devices.
Askar M; Hsich E; Reville P; Nowacki AS; Baldwin W; Bakdash S; Daghstani J; Zhang A; Klingman L; Smedira N; Moazami N; Taylor DO; Starling RC; Gonzalez-Stawinski G
J Heart Lung Transplant; 2013 Dec; 32(12):1241-8. PubMed ID: 24075503
[TBL] [Abstract][Full Text] [Related]
4. LVAD implant as a bridge to heart transplantation is associated with allosensitization as measured by single antigen bead assay.
Shankar N; Daly R; Geske J; Kushwaha SK; Timmons M; Joyce L; Stulak J; Gandhi M; Kremers W; Park S; Pereira NL
Transplantation; 2013 Aug; 96(3):324-30. PubMed ID: 23743727
[TBL] [Abstract][Full Text] [Related]
5. De Novo Human Leukocyte Antigen Allosensitization in Heartmate 3 Versus Heartmate II Left Ventricular Assist Device Recipients.
Jain R; Habal MV; Clerkin KJ; Latif F; Restaino SW; Zorn E; Takeda K; Naka Y; Yuzefpolskaya M; Farr MA; Colombo PC; Sayer GT; Uriel N; Topkara VK
ASAIO J; 2022 Feb; 68(2):226-232. PubMed ID: 33883507
[TBL] [Abstract][Full Text] [Related]
6. Outcomes after heart transplantation in sensitized patients bridged with ventricular assist devices.
Fraser CD; Zhou X; Magruder JT; Suarez-Pierre A; Lui C; Grimm JC; Higgins R; Kilic A
J Card Surg; 2019 Jun; 34(6):474-481. PubMed ID: 31045281
[TBL] [Abstract][Full Text] [Related]
7. Immunologic effects of continuous-flow left ventricular assist devices before and after heart transplant.
Ko BS; Drakos S; Kfoury AG; Hurst D; Stoddard GJ; Willis CA; Delgado JC; Hammond EH; Gilbert EM; Alharethi R; Revelo MP; Nativi-Nicolau J; Reid BB; McKellar SH; Wever-Pinzon O; Miller DV; Eckels DD; Fang JC; Selzman CH; Stehlik J;
J Heart Lung Transplant; 2016 Aug; 35(8):1024-30. PubMed ID: 27316382
[TBL] [Abstract][Full Text] [Related]
8. Effect of sensitization in US heart transplant recipients bridged with a ventricular assist device: update in a modern cohort.
Arnaoutakis GJ; George TJ; Kilic A; Weiss ES; Russell SD; Conte JV; Shah AS
J Thorac Cardiovasc Surg; 2011 Nov; 142(5):1236-45, 1245.e1. PubMed ID: 21839482
[TBL] [Abstract][Full Text] [Related]
9. De novo human leukocyte antigen allosensitization patterns in patients bridged to heart transplantation using left ventricular assist devices.
Chau VQ; Feinman J; Fullin K; Mahmood K; Oliveros E; Mitter SS; Pinney SP; Mancini DM; Lala A; Moss N
Transpl Immunol; 2022 Jun; 72():101567. PubMed ID: 35278648
[TBL] [Abstract][Full Text] [Related]
10. Factors influencing HLA sensitization in implantable LVAD recipients.
Massad MG; Cook DJ; Schmitt SK; Smedira NG; McCarthy JF; Vargo RL; McCarthy PM
Ann Thorac Surg; 1997 Oct; 64(4):1120-5. PubMed ID: 9354538
[TBL] [Abstract][Full Text] [Related]
11. Development of anti-major histocompatibility complex class I or II antibodies following left ventricular assist device implantation: effects on subsequent allograft rejection and survival.
Pagani FD; Dyke DB; Wright S; Cody R; Aaronson KD
J Heart Lung Transplant; 2001 Jun; 20(6):646-53. PubMed ID: 11404170
[TBL] [Abstract][Full Text] [Related]
12. Allosensitization in bridge to transplant Novacor left ventricular assist device patients: analysis of long-term outcomes with regard to acute rejection and chronic allograft vasculopathy.
Kirsch L; Timmermans T; Van Caenegem O; Gurne O; Noirhomme P; Jacquet LM; Latinne D; Poncelet AJ
Eur J Cardiothorac Surg; 2008 Aug; 34(2):268-74; discussion 274. PubMed ID: 18456505
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with anti-human leukocyte antigen antibodies in patients supported with continuous-flow devices and effect on probability of transplant and post-transplant outcomes.
Alba AC; Tinckam K; Foroutan F; Nelson LM; Gustafsson F; Sander K; Bruunsgaard H; Chih S; Hayes H; Rao V; Delgado D; Ross HJ
J Heart Lung Transplant; 2015 May; 34(5):685-92. PubMed ID: 25638296
[TBL] [Abstract][Full Text] [Related]
14. Avoidance of cellular blood product transfusions in LVAD recipients does not prevent HLA allosensitization.
Stringham JC; Bull DA; Fuller TC; Kfoury AG; Taylor DO; Renlund DG; Karwande SV
J Heart Lung Transplant; 1999 Feb; 18(2):160-5. PubMed ID: 10194040
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and risks of allosensitization in HeartMate left ventricular assist device recipients: the impact of leukofiltered cellular blood product transfusions.
Drakos SG; Stringham JC; Long JW; Gilbert EM; Fuller TC; Campbell BK; Horne BD; Hagan ME; Nelson KE; Lindblom JM; Meldrum PA; Carlson JF; Moore SA; Kfoury AG; Renlund DG
J Thorac Cardiovasc Surg; 2007 Jun; 133(6):1612-9. PubMed ID: 17532964
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes in sensitized heart transplant patients bridged with ventricular assist devices.
Kidambi S; Mohamedali B; Bhat G
Clin Transplant; 2015 Jun; 29(6):499-505. PubMed ID: 25773536
[TBL] [Abstract][Full Text] [Related]
17. Impact of left ventricular assist device (LVAD)-mediated humoral sensitization on post-transplant outcomes.
Joyce DL; Southard RE; Torre-Amione G; Noon GP; Land GA; Loebe M
J Heart Lung Transplant; 2005 Dec; 24(12):2054-9. PubMed ID: 16364849
[TBL] [Abstract][Full Text] [Related]
18. Detection of anti-HLA antibody by flow cytometry in patients with a left ventricular assist device is associated with early rejection following heart transplantation.
DeNofrio D; Rho R; Morales FJ; Kamoun M; Kearns J; Dorozinsky C; Rosengard BR; Acker MA; Loh E
Transplantation; 2000 Mar; 69(5):814-8. PubMed ID: 10755532
[TBL] [Abstract][Full Text] [Related]
19. Characterization of ventricular assist device-mediated sensitization in the bridge-to-heart-transplantation patient.
Kwon MH; Zhang JQ; Schaenman JM; Cadeiras M; Gjertson DW; Krystal CA; Laks H; Ardehali A; Deng MC; Shemin RJ; Reed EF
J Thorac Cardiovasc Surg; 2015 Apr; 149(4):1161-6. PubMed ID: 25702320
[TBL] [Abstract][Full Text] [Related]
20. The effect of paracorporeal pulsatile biventricular assist devices on allosensitization in adults: A comparison with left ventricular assist devices.
Chaidaroglou A; Armenis I; Gkouziouta A; Bonios MJ; Kogerakis N; Fragoulis S; Leontiadis E; Zarkalis D; Stavridis G; Kaklamanis L; Adamopoulos S; Degiannis D
Transpl Immunol; 2021 Dec; 69():101477. PubMed ID: 34600071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
